Recommended

FDA tightens COVID vaccine use
Decentralised manufacturing consortium launched
Trial boost for myasthenia gravis drug
FDA starts publishing daily AE data
WEBINAR | The Future of Sterility Testing: One-Day Results with Advanced RT-rt PCR Technology | 5 NOV
WEBINAR | Mastering Impurity Profiling: USP’s Evolving Standards and Strategies | 15 OCT
news

New immuno-oncology treatment approved for endometrial cancer

3
SHARES

The first new treatment option approved for mismatch repair deficient (dMMR)/microsatellite instability-high (MSI-H) primary advanced or recurrent endometrial cancer in decades has been authorised by the US Food and Drug Administration (FDA).

New immuno-oncology treatment Jemperli plus chemotherapy approved for endometrial cancer

The only immuno-oncology treatment approved as frontline therapy for mismatch repair deficient (dMMR) or microsatellite instability-high (MSI-H), primary advanced or recurrent endometrial cancer in combination with chemotherapy, is now authorised in the US. Jemperli (dostarlimab), a programmed death receptor-1 (PD-1)-blocking antibody, has been approved by the US Food and Drug Administration (FDA).

 

ACCESS your FREE COPY

 


This report addresses the key factors shaping pharmaceutical formulation, including regulation, QC and analysis.

Access the full report now to discover the techniques, tools and innovations that are transforming pharmaceutical formulation, and learn how to position your organisation for long-term success.

What you’ll discover:

  • Key trends shaping the pharmaceutical formulation sector
  • Innovations leading progress in pharmaceutical formulation and how senior professionals can harness their benefits
  • Considerations and best practices when utilising QbD during formulation of oral solid dosage forms
  • And more!

Don’t miss your chance to access this exclusive report ! Access now – it’s free

The biologic is authorised for use in combination with carboplatin and paclitaxel, followed by Jemperli as a single agent for treating adults with dMMRMSI-H primary advanced or recurrent endometrial cancer.

“Today’s expanded approval of Jemperli redefines the treatment landscape” for these patients, according to Hesham Abdullah, Senior Vice President, Global Head of Oncology Development at GSK.

Positive data for the Jemperli immuno-oncology treatment 

“In the RUBY trial, Jemperli plus chemotherapy demonstrated a 71 percent reduction in the risk of disease progression or death versus chemotherapy in this patient population, providing a statistically significant and clinically meaningful benefit,” shared Abdullah.

With this approval, Jemperli is now indicated earlier in treatment in combination with chemotherapy.

The FDA approval is supported by interim analysis results from Part 1 of the RUBY/ENGOT-EN6/GOG3031/NSGO Phase III trial.

The RUBY trial data were presented at the European Society for Medical Oncology (ESMO) Virtual Plenary and Society of Gynecologic Oncology (SGO) Annual Meeting on 27 March 2023, and were simultaneously published in The New England Journal of Medicine.

In the US, Jemperli is indicated in combination with carboplatin and paclitaxel, followed by Jemperli as a single agent for adults with primary advanced or recurrent endometrial cancer that is dMMR. This is alongside as a single agent for adults with dMMR recurrent or advanced endometrial cancer, that has progressed on or following a prior platinum-containing regimen in any setting and are not candidates for curative surgery or radiation.

The supplemental Biologics License Application (sBLA) supporting the new indication in combination with carboplatin and paclitaxel received Breakthrough Therapy designation (BTD) from the FDA.

FDA approves Jemperli for advanced endometrial cancer

Share via
Share via